Publication:
Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy: results from a contemporary Turkish patient cohort

dc.contributor.coauthorTinay, Ilker
dc.contributor.coauthorAslan, Guven
dc.contributor.coauthorKural, Ali Riza
dc.contributor.coauthorOzen, Haluk
dc.contributor.coauthorAkdogan, Bulent
dc.contributor.coauthorYildirim, Asif
dc.contributor.coauthorOngun, Sakir
dc.contributor.coauthorOzkan, Alp
dc.contributor.coauthorZorlu, Ferruh
dc.contributor.coauthorDillioglugil, Ozdal
dc.contributor.coauthorBekiroglu, Nural
dc.contributor.coauthorTurkeri, Levent
dc.contributor.kuauthorEsen, Tarık
dc.contributor.kuprofileFaculty Member
dc.contributor.yokid50536
dc.date.accessioned2024-11-09T23:21:47Z
dc.date.issued2018
dc.description.abstractIntroduction: To evaluate the pathological outcomes of Turkish men meeting the criteria for Active Surveillance (AS), who elected to undergo immediate radical prostatectomy (RP). Material and Methods: Retrospective analysis including 1,212 patients with clinically localized prostate cancer (PCa) who met the eligibility criteria for AS. The primary outcomes were pathological upstaging and pathological upgrading. Results: Nine hundred ninety-one patients were eligible for analysis after the central review of the submitted data. The mean prostate-specific antigen (PSA) level was 6.89 (0.51-15) ng/mL and the mean biopsy core number was 12 (8-47). The mean tumor positive core on final biopsy pathology was 1.95 (1-6) (16.6% [2.1-33.3%]). Overall, 30.6% of the men experienced a Gleason sum (GS) upgrade and 13.2% had pathological upstaging. For GS upgrade, the percentage of tumor-positive cores and free-to-total-PSA ratio were significant both in univariate analysis and multivariate logistic regression analysis. Variables predicting pathological upstaging were percentage of tumor-positive cores and PSA density, which were significant in univariate analysis. However, only PSA density was significant in multivariate logistic regression. Although biochemical recurrence-free survival was longer in patients without GS upgrade, it was not statistically significant between patients with and without any GS upgrade (mean 133.7 vs. 148.2 months, p = 0.243). A similar observation was made for patients with or without pathological upstaging (mean 117.1 vs. 148.3 months, p = 0.190). Conclusions: Upgrading and upstaging at RP are quite common among Turkish men with clinically low-risk PCa, who are candidates for AS, and a great majority of them experienced long-term PSA control. (c) 2017 S. Karger AG, Basel
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue1
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume100
dc.identifier.doi10.1159/000481266
dc.identifier.eissn1423-0399
dc.identifier.issn0042-1138
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85040068111
dc.identifier.urihttp://dx.doi.org/10.1159/000481266
dc.identifier.urihttps://hdl.handle.net/20.500.14288/10955
dc.identifier.wos423837100007
dc.keywordsProstate cancer
dc.keywordsActive surveillance
dc.keywordsRadical prostatectomy
dc.languageEnglish
dc.publisherKarger Publishers
dc.sourceUrologia Internationalis
dc.subjectUrology and nephrology
dc.titlePathologic outcomes of candidates for active surveillance undergoing radical prostatectomy: results from a contemporary Turkish patient cohort
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-0961-9374
local.contributor.kuauthorEsen, Tarık
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine

Files